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Overexpression of FOXG1 contributes to TGF-b resistance
through inhibition of p21WAF1/CIP1 expression in ovarian cancer
DW Chan1, VWS Liu1, RMY To1, PM Chiu1, WYW Lee1, KM Yao2, ANY Cheung3 and HYS Ngan*,1
1Department of Obstetrics and Gynaecology, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, P. R. China; 2Department of
Biochemistry, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, P. R. China; 3Department of Pathology, LKS Faculty of Medicine,
University of Hong Kong, Hong Kong SAR, P. R. China
BACKGROUND: Loss of growth inhibitory response to transforming growth factor-b (TGF-b) is a common feature of epithelial cancers.
Recent studies have reported that genetic lesions and overexpression of oncoproteins in TGF-b/Smads signalling cascade contribute
to the TGF-b resistance. Here, we showed that the overexpressed FOXG1 was involved in attenuating the anti-proliferative control
of TGF-b/Smads signalling in ovarian cancer.
METHODS: FOXG1 and p21WAF1/CIP1 expressions were evaluated by real-time quantitative reverse-transcription polymerase chain
reaction (RT–PCR), western blot and immunohistochemical analyses. The effect of FOXG1 on p21WAF1/CIP1 transcriptional activity
was examined by luciferase reporter assays. Cell lines stably expressing or short hairpin RNA interference-mediated knockdown
FOXG1 were established for studying the gain-or-loss functional effects of FOXG1. XTT cell proliferation assay was used to measure
cell growth of ovarian cancer cells.
RESULTS: Quantitative RT–PCR and western blot analyses showed that FOXG1 was upregulated and inversely associated with the
expression levels of p21WAF1/CIP1 in ovarian cancer. The overexpression of FOXG1 was significantly correlated with high-grade ovarian
cancer (P¼ 0.025). Immunohistochemical analysis on ovarian cancer tissue array was further evidenced that FOXG1 was highly
expressed and significantly correlated with high-grade ovarian cancer (P¼ 0.048). Functionally, enforced expression of FOXG1
selectively blocked the TGF-b-induced p21WAF1/CIP1 expressions and increased cell proliferation in ovarian cancer cells. Conversely,
FOXG1 knockdown resulted in a 20–26% decrease in cell proliferation together with 16–33% increase in p21WAF1/CIP1 expression.
Notably, FOXG1 was able to inhibit the p21WAF1/CIP1 promoter activity in a p53-independent manner by transient reporter assays.
CONCLUSION: Our results suggest that FOXG1 acts as an oncoprotein inhibiting TGF-b-mediated anti-proliferative responses in
ovarian cancer cells through suppressing p21WAF1/CIP1 transcription.
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The transforming growth factor-b (TGF-b) family consists of
multifunctional cytokines that control a wide variety of biological
activities including cell proliferation, differentiation, apoptosis,
cell adhesion, extracellular matrix formation, immune cell regula-
tion and embryonic development through activating TGF-b
receptors and Smad transducer proteins (Hu et al, 1998; Massague,
1998). The complicated role of TGF-b in mediating these cellular
activities depends on cell types, growth environment, concentra-
tion of ligands and the presence of other growth factors (Hu et al,
1998; Massague, 1998; Savage-Dunn, 2005). Inhibition of cell
proliferation is one of the biological effects of TGF-b on normal
epithelial cells, suggesting that TGF-b acts as a tumour suppressor
(Moses et al, 1987). Loss of autocrine activity and/or responsive-
ness to TGF-b is frequently found in human cancers during
tumour progression. Mutations, deletions or methylation of
members of TGF-b signalling pathway leading to TGF-b resistance
in human cancers have been extensively reported. For examples,
decreased expressions or mutations in TGF-b R1, TGF-b RII and
Smad4 have been frequently detected in a number of human
cancers. (Eisma et al, 1996; Kim et al, 1996; Ko et al, 1998;
Korchynskyi et al, 1999; Matsushita et al, 1999; Venkatasubbarao
et al, 2000; Maurice et al, 2001; Paik et al, 2003; Sakaguchi et al,
2005; Perttu et al, 2006; Zhong et al, 2006).
On the other hand, elevated expression of proto-oncogenes or
oncogenes may also cause TGF-b resistance in tumour cells. For
example, upregulation of the c-Ski and SnoN represses the growth
inhibitory function of the Smad proteins (He et al, 2003); increased
expression of the oncoprotein HER2/Neu activates Smad7
transcription (Dowdy et al, 2003), and overexpression of BCL6
disrupts the Smad-p300 interaction and represses the transcrip-
tional activity of Smad4 (Wang et al, 2008). Moreover, increased
expression of the EWS/Fli1 oncogene, the Tax oncoprotein from
HTLV-1, the E1A oncoprotein of DNA virus and the E7
oncoprotein of HPV resulted in reduced TGF-b responsiveness
(Datta and Bagchi, 1994; Hahm et al, 1999; Mori et al, 2001; Lee
et al, 2002). Given the important tumour suppressor functions of
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the TGF-b pathway, it is expected that other oncoproteins could
promote tumourigenesis by counteracting this pathway.
FOXG1, also known as brain factor-1, is a member of Forkhead
box family of transcription factors (Arden, 2004; Obendorf et al,
2007). FOXG1 contains a highly conserved DNA-binding domain,
which binds to specific DNA sequences and regulates gene
expression (Yao et al, 2001). Recent studies have shown that
FOXG1 acts as a negative regulator of TGF-b signalling pathway by
specifically binding to the Smad MH2 domain and associates with
Smad -1, -2, -3 and -4 (Dou et al, 2000; Seoane et al, 2004). This
association blocks the binding of Smad proteins to DNA and
results in the inhibition of TGF-b signalling (Rodriguez et al,
2001). In addition, FOXG1 has been shown to inhibit expression
of the cyclin-dependent kinase (CDK) inhibitor p21WAF1/CIP1,
which is normally transcriptionally activated by TGF-b signalling,
in glioblastoma and the neuroepithelium (Pardali et al, 2000;
Seoane et al, 2004). However, the functions of FOXG1 in other
human cancers remain unclear.
In this study, we reported that the FOXG1 was overexpressed
in ovarian cancer. The overexpressed FOXG1 was significantly
correlated with high-grade ovarian cancer. More importantly, we
showed that the increased expression of FOXG1 significantly
suppressed the expression of p21WAF1/CIP1 and increased cell
proliferation of ovarian cancer cells. Altogether, these findings
suggest that FOXG1 was associated with attenuating the TGF-b
anti-proliferative response in ovarian cancer.
MATERIALS AND METHODS
Clinical samples and cell lines
Sixty-seven ovarian cancer tissues and 49 normal ovarian tissues
were obtained from the Department of Obstetric and Gynaecology
at Queen Mary hospital. The histological subtypes and disease
stages of the ovarian tumours were classified according to the
International Federation of Gynaecology and Obstetrics (FIGO)
criteria. All the clinical specimens used in this study were
approved by the local institutional ethics committee (Institutional
Review Board number: UW05-143 T1806). Four immortalised
human ovarian surface epithelial (HOSE) cells were used in this
study: HOSE 6-3, HOSE 10-2, HOSE 11-12, HOSE 17-1 and HOSE
11-24 (from Prof George Tsao, the University of Hong Kong).
Ovarian cancer cell lines OV2008, C13*, A2780s, A2780cp (gift
from Prof Benjamin Tsang, University of Ottawa), OVCAR3,
SKOV3, OV420, OV429 and OV433 (American Type Culture
Collection, Rockville, MD, USA) were used in this study. All were
grown at 371C in 5% CO2 in minimum essential medium or
Dulbecco’s modified Eagle medium supplemented with 10% foetal
bovine serum.
Plasmids and cell transfection
The pCMV2-Flag-FOXG1-expressing plasmid (gift from Dr Stefano
Stifani from McGill University, Montreal, Quebec, Canada) was used
for ectopic expression of Flag-tagged FOXG1. The short hairpin
RNA interference (shRNAi) targeting FOXG1 (target sequence:
TCTGTCCCTCAACAAGTGC) was ligated into pTER vector (gift
from Dr Marc van de Wetering, Centre for Biochemical Genetics,
the Netherlands) to generate pTER-shFOXG1 plasmid. A human
mutant p21WAF1/CIP1 promoter luciferase construct (pWWP)
containing a truncated p21WAF1/CIP1 promoter with deleted p53-
binding sites (gift from Dr Mark Feitelson, Mercer Laboratory,
Thomas Jefferson University, Philadelphia, PA, USA) was used for
luciferase reporter assay. LipofectAMINE 2000 (Invitrogen Life
Technologies, Carlsbad, CA, USA) and Fugene6 Transfection
Reagent (Roche Biosciences, Indianapolis, IN, USA) were used
for cell transfection according to the manufacturer’s instructions.
The pcDNA3 and pTER empty vectors were used as mock
transfection, respectively, in enforced expression and knockdown
assays, whereas pRL-SV40 (Promega, Madison, WI, USA) was
served as an internal control in luciferase reporter assay. Stably
overexpressed Flag-tagged FOXG1 or FOXG1 knockdown clones
were established by drug selection using G418 at 400mgml1 for
2 weeks or puromycin at 2 mgml1 for 1 week, respectively.
Positive clones were randomly chosen for cell number expansion
and verified by western blot analysis.
Quantitative and semi-quantitative reverse-transcription
polymerase chain reaction
Total RNA from each cell line was prepared by TRIzol reagent
(Invitrogen). First strand cDNA was synthesised by random
hexamers and Taqman reverse transcription reagent kit (Applied
Biosystems, Foster City, CA, USA). For real-time quantitative
reverse-transcription polymerase chain reaction (RT–PCR)
(Q-PCR), the amount of FOXG1 and p21WAF1/CIP1 genes were
quantified by TaqMan Gene Expression Assays and in an ABI 7700
system (Applied Biosystems) using the FOXG1 and p21WAF1/CIP1
primers and probe from Applied Biosystems (FOXG1, assay ID:
Hs00702391_s1; p21WAF1/CIP1, assay ID: Hs00355782; GAPDH,
assay ID: Hs99999905_m1). Each sample was performed in
triplicate and normalised with human GAPDH (assay ID:
Hs99999905_m1; Applied Biosystem). For semi-quantitative
RT–PCR, the p21WAF1/CIP1 mRNA level was evaluated by a pair
of primers (p21WAF1/CIP1-Sense 50-ACCATGTGGACCTGTCACTGT
CTT-30 and p21WAF1/CIP1-Antisense 50-AGAAGATGTAGAGCGGGC
CTTTGA-30) with the following conditions for 30–35 cycles:
denaturation at 941C for 30 sec, annealing at 581C for 30 sec and
extension at 721C for 30 sec. The relative amount of p21WAF1/CIP1
was normalised using GAPDH mRNA with the following primers
(GAPDH-Sense: 50-ACGCATTTGGTCGTATTGGG-30 and GAPDH-
Antisense: 50-TGATTTTGGAGGGATCTCGC-30) and amplification
at 25 cycles: denaturation at 941C for 30 sec, annealing at 551C for
30 sec and extension at 721C for 1min.
Immunohistochemical and western blot analyses
Immunohistochemical staining for FOXG1 was performed on
an ovarian cancer tissue array (OVC961) (Pantomics Inc,
San Francisco, CA, USA). The section was immunostained with
primary rabbit polyclonal anti-FOXG1 antibody (Abcam Inc,
Cambridge, MA, USA) in 1 : 20 dilution. For negative controls,
the primary antibody was replaced with Tris-buffered saline.
The intensity of staining was scored as 0 (negative), 1þ (faint),
2þ (moderate), 3þ (strong) and 4þ (marked).
For western blot analysis, samples containing equal amounts
of protein were separated by SDS–PAGE and electroblotted onto
Hybond-P membranes (Amersham Pharmacia Biotech, Cleveland,
OH, USA). Blots were blotted with 5% skimmed milk and analysed
by immunoblotting with antibodies specific for anti-FOXG1
(Abcam), anti-Flag, anti-b-actin and anti-phosphoserine (Sigma
Chemical Co, St Louis, MO, USA), anti-p21WAF1/CIP1, anti-Smad3
and anti-phospho-Smad3 (Cell Signalling Technology, Darvers,
MA, USA) and anti-Histone H1 (Santa Cruz Biotechnology Inc,
Santa Cruz, CA, USA). Blots were then incubated with goat anti-
mouse or anti-rabbit secondary antibodies conjugated to horse-
radish peroxidase (Amersham) and visualised by enhanced
chemiluminescence (ECL) (Amersham).
Subcellular fractionation and phosphorylation studies
The cellular localisation of endogenous FOXG1 or Flag-tagged
FOXG1 in ovarian cancer cells was examined by western blot
analysis on subcellular extracts prepared from NE-PER nuclear and
cytoplasmic extraction reagents according to the manufacturer’s
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protocol (Pierce Biotechnology, Rockford, IL, USA). The serine
phosphorylation status of FOXG1 in ovarian cancer cells was
analysed according to Regad et al (2007). Briefly, ovarian cancer
cells were collected in NET lysis buffer (50mM Tris, pH 7.4, 150mM
NaCl and 5mM EDTA) with 1% NP40, pH 8.0, 0.1mM PMSF and
1mM Complete TM protease inhibitor cocktail (Roche). FOXG1 or
Flag-tagged FOXG1 was immunopreciptated from 500 ng whole
cell lysates by 0.5 mg of anti-FOXG1 (Santa Cruz) by incubation
with Protein A/G Plus-Agarose beads (Santa Cruz) at 41C.
Immunoprecipitates on the beads were washed four times with
NET lysis buffer, followed by elution using SDS sample buffer (Cell
Signalling) and denature by boiling before electrophoresis.
Luciferase reporter assay
Cells were seeded in 24-well plates and transiently transfected
with various amounts of pCMV2-Flag-FOXG1 vector with pWWP-
luciferase reporter construct. Cells were incubated with the
transfection reagents for at least 24 h and were then replaced with
fresh medium containing 100 pM TGF-b. After 5 h of TGF-b
incubation, cells were lysed for luciferase activity analysis using the
Dual-Luciferase Reporter Assay System (Promega). The transfec-
tion efficiency was normalised with Renilla luciferase activity. All
experiments were repeated three times.
Cell viability analysis
Cell viability was measured by Cell Proliferation kit II (XTT) for
5 days according to the manufacturer’s instructions (Roche).
The experiment was performed in triplicate for each time point.
Human TGF-b1 was purchased as lyophilised samples from
R&D systems (Minneapolis, MN, USA). Sterile 4mM HCl (Merck,
Darmstadt, Germany) containing 0.1% (v/v) bovine serum
albumin (Pierce) was added to prepare a stock solution of
10 mgml1.
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Figure 1 FOXG1 is underexpressed and is inversely correlated with p21WAF1/CIP1 in normal ovaries and ovarian cancer tissues. (A) Western blot analysis
showed the expression of FOXG1 in ovarian cancer cell lines and immortalised normal ovarian epithelial cell lines (HOSEs). (B) The relative expression
levels of FOXG1 was evaluated by quantitative RT–PCR on HOSEs, normal ovaries and four histological subtypes of ovarian cancers (*Po0.001;
**P¼ 0.0076). N is the number of subtype cases. (C) Quantitative RT–PCR showed the expression level of FOXG1 and p21WAF1/CIP1 in normal ovaries and
ovarian cancer tissues. The values were obtained by mean±s.e.m. (*P¼ 0.001; **Po0.0001).
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Statistical analysis
Student’s t test (for parametric data) and the Mann–Whitney
test (for non-parametric data) were used. Correlation of gene
expression was analysed using Spearman’s rho non-parametric
statistics. Statistical analyses on clinicopathological correlation
were performed using the SPSS version 13.0 software (SPSS,
Chicago, IL, USA). A P-value was considered significant when
o0.05.
RESULTS
Overexpression of FOXG1 in ovarian cancer
Our preliminary data using cDNA microarray analysis has shown
that the expression of FOXG1 in ovarian cancer cell lines was
2.2-folds higher than that in HOSE cells (Liu et al, unpublished
data). In this study, we found that four out of nine ovarian cancer
cell lines (SKOV3, C13*, A2780s and A2780cp) expressed relatively
higher levels of FOXG1 as compared with four HOSEs cell lines by
western blotting (Figure 1A). To further confirm the upregulation
of FOXG1 in ovarian cancer, we evaluated the expression status
of FOXG1 in ovarian cancer tissues (n¼ 67) and normal ovarian
tissues (n¼ 49) by Q-PCR analysis. On the basis of comparative
CT method using GAPDH as the endogenous control, very low
expression level of FOXG1 was detected in normal ovaries and
HOSEs (Figure 1B). Conversely, FOXG1 expression was signi-
ficantly higher in serous, mucinous, endometrioid (Po0.001)
and clear cell/undifferentiated (P¼ 0.0076) subtypes of ovarian
tumours when compared with the normal ovaries (Figure 1B).
As earlier studies have shown that FOXG1 is able to block the
transcription of p21WAF1/CIP1 by counteracting TGF-b-induced
signalling pathway and hence promoting cell proliferation (Seoane
et al, 2004; Adesina et al, 2007a), it would be interesting to examine
the gene expression of p21WAF1/CIP1 in normal ovaries and ovarian
cancer tissues. Using Q-PCR analysis, we found that p21WAF1/CIP1
showed higher expression levels in normal ovarian tissues when
compared with ovarian tumour (Po0.0001) (Figure 1C). In addi-
tion, the expression status of p21WAF1/CIP1 was inversely associated
with FOXG1 (Figure 1C). However, no statistical significant
negative correlation was found for FOXG1 and p21WAF1/CIP1
expressions using non-parametric Spearman rho test (r¼0.05,
P40.05).
Clinicopathological correlation of FOXG1 and ovarian
cancer
On clinicopathological correlation, we found that the FOXG1
overexpression (41.5-fold) in ovarian cancer was significantly
correlated with high-grade tumour (P¼ 0.025) (Table 1). However,
there was no association with any histological subtypes of ovarian
cancers (serous, mucinous, endometrioid and clear cell), tumour
stage, recurrence and age (Table 1), as well as the patient’s survival
(data not shown). This indicates that the overexpression of FOXG1
does not link to any specific subtypes, tumour stage and patient’s
survival but is involved in high-grade tumours of ovarian cancer.
Immunohistochemical analysis of FOXG1 expression in
ovarian cancer tissue array
Expression of FOXG1 was also assessed by immunohistochemical
staining in ovarian cancer tissue array (OVC961) (Pantomics Inc),
which has 31 cases of epithelial ovarian cancer with different
histological subtypes (serous, mucinous, endometrioid, clear cell/
undifferentiated) and 6 cases of normal and benign tumour tissues.
FOXG1 protein expression was evaluated as 0 (negative), 1þ
(faint), 2þ (moderate), 3þ (strong) and 4þ (marked). FOXG1
staining was observed in 80.6% (25 out of 31) of ovarian carci-
nomas examined whereas positive staining was rarely observed in
the epithelial cells of normal ovarian and benign tumour tissues
(Figure 2A) (Table 2). Positive staining of FOXG1 was observed
in 100.0% (9 out of 9) serous, 66.7% (4 out of 6) mucinous, 84.6%
(11 out of 13) endometrioid and 33.3% (1 out of 3) clear cell/
undifferentiated ovarian cancer (Table 2) (Figure 2B–E). Of 29
ovarian cancer cases with tumour grade and stage scores, high
intensity (43þ ) of FOXG1 was significantly correlated with high-
grade tumour (P¼ 0.048) but no association was found for tumour
stage (data not shown). This finding was consistent with the
quantitative RT–PCR data. Besides, FOXG1 expression was mainly
localised in the cytoplasm, but nuclear localisation of FOXG1 was
also detected (Figure 2F), suggesting that FOXG1 exhibits
nucleocytoplasmic shuttling and has different functions in cells.
The effect of TGF-b on ovarian cancer cells
To examine whether the overexpressed FOXG1 exerts inhibitory
role on TGF-b-induced p21WAF1/CIP1 expression similar to earlier
reports (Seoane et al, 2004; Adesina et al, 2007a), several ovarian
cancer cell models were used. Genetic and/or epigenetic lesions
usually deregulate TGF-b-mediated cell growth inhibitory effects
in various human cancers, including ovarian cancer (Sakaguchi
et al, 2005). To exclude ovarian cancer cell lines with malfunc-
tioned TGF-b signalling, we tested the TGF-b/Smad signalling
component, Smad3 and the p21WAF1/CIP1 gene induction under
TGF-b treatment for the selected cell lines. To test the effect of
TGF-b on ovarian cancer cell lines, cells were cultured in the
presence or absence of 100 pM TGF-b in serum-free medium for 5 h
and were then collected for immunoblotting. As Smad3 is one of
the key effectors of TGF-b signalling, the levels of Smad3 and
phosphorylated Smad3, which represent the activated form of
Smad3, were examined.
Table 1 Clinicopathological correlation of FOXG1 expression in ovarian
cancer patients
FOXG1 expression (fold)
Characteristics Total p1.5 41.5 P
All cases 67 33 (49.25%) 34 (50.75%)
Age (y)
o55 39 16 (41.03%) 23 (58.97%)
455 28 17 (60.71%) 11 (39.29%) 0.112
Stage
Early 21 12 (57.14%) 9 (42.86%)
Late 43 21 (48.84%) 22 (51.16%) 0.532
Grade
1 and 2 20 14 (70.00%) 6 (30.00%)
3 29 11 (37.93%) 18 (62.07%) 0.027*
Histological subtypes
Serous+/papillary 21 13 (61.90%) 8 (38.10%)
Others 46 20 (43.48%) 26 (56.52%) 0.162
Mucinous 14 5 (35.71%) 9 (64.29%)
Others 53 28 (52.83%) 25 (47.17%) 0.255
Endometrioid 17 7 (41.18%) 10 (58.82%)
Others 50 26 (52.00%) 24 (48.00%) 0.441
Clear cells/undifferentiated 15 8 (53.33%) 7 (46.67%)
Others 52 25 (48.08%) 27 (51.92%) 0.720
Recurrence
+ 31 15 (48.39%) 16 (51.61%)
 31 16 (51.61%) 15 (48.39%) 0.799
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On TGF-b treatment, activation of Smad3 was observed in
OVCA420, OVCA429, OVCA433, SKOV3, A2780s and A2780cp
cells, but activation of Smad3 was not observed in OV2008 and
C13* after TGF-b treatment (Figure 3A). Moreover, by semi-
quantitative RT–PCR and western blot analyses, induction of
p21WAF1/CIP1 expression was observed in OVCA420, OVCA429,
SKOV3, A2780s and A2780cp (Figure 3B and C). As these five cell
lines also showed Smad3 activation on TGF-b treatment, we
believe that these cell lines are still responsive to the inhibitory
effect of TGF-b signalling. However, OVCA433, which showed
Smad3 activation in the presence of TGF-b, failed to show
p21WAF1/CIP1 induction after TGF-b addition. It is suspected that
the TGF-b signalling pathway downstream of Smad3 has been
disrupted in OVCA433. Taken together, five of the ovarian cancer
cell lines studied (OVCA420, OVCA429, SKOV3, A2780s and
A2780cp) acquire a functional TGF-b signalling pathway and
are able to drive the transcriptional activation of p21WAF1/CIP1 on
TGF-b treatment.
FOXG1 inhibits p21WAF1/CIP1 promoter activity on TGF-b
treatment
To determine whether FOXG1 regulates p21WAF1/CIP1 expression at
the transcriptional level, luciferase reporter assay was conducted.
As it has been well known that p21WAF1/CIP1 is a downstream target
of p53, truncated p21WAF1/CIP1 promoter without p53-binding site
(pWWP) was used to ensure that the change of p21WAF1/CIP1
promoter activity was independent of p53 regulation. On
transfection of FOXG1 at increasing amounts (0, 150, 250 and
300 ng) and treatment of TGF-b (100 pM), the relative luciferase
activity of p21WAF1/CIP was reduced from 100% to 25%, 19% and
11%, respectively, in HEK293T cells (Po0.05), and from 100%
to 79%, 65% and 60%, respectively, in A2780cp cells (Po0.05)
(Figure 4A and B). These data suggest that FOXG1 regulates the
expression of p21WAF1/CIP1 at the transcriptional level in HEK293T
as well as A2780cp ovarian cancer cells.
Enforced expression of FOXG1 inhibits p21WAF1/CIP1
induction and increases cell proliferation on TGF-b
treatment
To investigate the inhibitory function of FOXG1 on TGF-b-induced
p21WAF1/CIP1 expression and cell proliferation, we first generated
Flag-tagged FOXG1 stable-expressing clones from two ovarian
cancer cell lines, SKOV3 and A2780cp (Figure 5A and B). On
TGF-b treatment, a 2.6-fold and 1.5-fold induction of p21WAF1/CIP1
A B
C D
E F
Figure 2 Immunohistochemical analyses of FOXG1 expression in ovarian cancer tissues. FOXG1 staining in (A) benign, (B) clear cell/undifferentiated,
(C) mucinous, (D) serous and (E) endometrioid ovarian cancers. (F) Cytoplasmic and nuclear localisation of FOXG1. Arrow, nuclear localisation of FOXG1.
Magnification:  200 (A, B, C, D and E), and  400 (F).
Table 2 Immunohistochemical scores of FOXG1 on tissue array of
ovarian cancer
Expression level (%)
Histological types Number of cases Negative 1+/2+ 3+/4+
Normal/benign tumour 6 5 (58.3) 1 (16.7) 0
Clear cell/undifferentiated 3 2 (66.7) 0 1 (33.4)
Serous 9 0 2 (22.2) 7 (77.8)
Mucinous 6 2 (33.3) 3 (50.0) 1 (16.7)
Endometrioid 13 2 (15.4) 2 (15.4) 9 (69.4)
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mRNA and protein levels were observed in SKOV3 and A2780cp
vector controls, respectively (Figure 5C). However, there was no
change in p21WAF1/CIP1 levels on TGF-b treatment for two stable
clones expressing Flag-tagged FOXG1 of both cell lines (SK-C18
and Acp-C4) (Figure 5C). This suggests that the overexpressed
FOXG1 suppresses TGF-b-induced p21WAF1/CIP1 expression. We
next examined the effect of enforced FOXG1 expression on cell
growth using in vitro proliferation assay (XTT assay). In the
presence of 10 pg TGF-b1 in cell culture medium, enforced
expression of FOXG1 in both stable clones exhibited a higher cell
proliferation rate (38% for SK-C18, Po0.05; and 48% for Acp-C4,
Po0.01) as compared with their vector control cell lines
(Figure 5D). These results suggest that FOXG1 promotes the cell
proliferation of ovarian cancer cells, which is consistent with the
role of FOXG1 in the inhibition of anti-proliferative effect of TGF-b
reported in earlier studies.
Depletion of FOXG1 sensitises TGF-b-mediated
p21WAF1/CIP1 induction and cell growth inhibition
To further confirm the inhibitory effect of FOXG1 on TGF-b
signalling in ovarian cancer cells, we used the vector-based RNAi
technique and successfully knockdown475% endogenous FOXG1
in an FOXG1 overexpressing cell lines, SKOV3 and A2780cp
(Figure 6A and B). On TGF-b treatment, additional increase of
p21WAF1/CIP1 expressions was observed in the FOXG1-depleted
clones of SKOV3 (16% increase in SK-shC8) and A2780cp (33%
increase in Acp-shC6) cells as compared with empty vector
controls (Figure 6B). XTT assay also demonstrated that depletion
of FOXG1 could reduce 26% (SK-shC8) and 20% (Acp-shC6) cell
proliferation rate (Po0.05) in the presence of 10 pg TGF-b in
SKOV3 and A2780cp cells, respectively (Figure 6C). These data
further support that FOXG1 counteracts TGF-b-mediated cell
growth arrest through regulation of p21WAF1/CIP1 induction.
Inhibition of p21WAF1/CIP1 induction because of increased
nuclear localisation of FOXG1
It has been shown that FOXG1 is able to block p21WAF1/CIP1
induction by interacting with FoxO–Smad complexes in nucleus
(Seoane et al, 2004). To examine whether the inhibition of
p21WAF1/CIP1 induction in overexpressed FOXG1 ovarian cancer
cells was due to the increased accumulation of nuclear FOXG1,
we conducted western blot analysis on subcellular extracts from
ovarian cancer cell lines. Of four ovarian cancer cell lines, a
relatively higher level of nuclear FOXG1 was observed in SKOV3
and A2780cp cells, which expressed relatively higher levels of
FOXG1 as compared with OVCA420 and OVCA429 cells (Figures
1A and 7A). We also found that a significant increase of nuclear
Flag-tagged FOXG1 was observed in Flag-tagged FOXG1 stably
expressing clone (Acp-C4) (Figure 7B). Conversely, a reduction in
nuclear FOXG1 was found in FOXG1 knockdown clone (Acp-shC6)
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Figure 5 Enforced expression of FOXG1 blocks the induction of p21WAF1/CIP1 and promotes cell proliferation on TGF-b treatment. (A, B) Western
blot analysis showed the expression of Flag-tagged FOXG1 in two stable clones, SK-C18 and Acp-C4, of SKOV3 and A2780cp ovarian cancer cell
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of A2780cp cells (Figure 7B). A recent finding has shown that the
elevation of phosphorylation at Ser19 of FOXG1 promotes nuclear
import (Regad et al, 2007). Thus, we attempted to evaluate the
serine phsophorylation levels of FOXG1 according to the similar
protocol of Regad et al (2007). By immunopreciptation and
western blot assays, an increase level of serine phosphorylation of
FOXG1 was detected in SKOV3 and A2780cp cells, and in Flag-
tagged FOXG1 stably expressing clone (Acp-C4) (Figure 7C and D).
These results show that the inhibition of p21WAF1/CIP1 induction in
FOXG1-overexpressed ovarian cancer cells is due to the increased
serine phosphorylation and nuclear localisation of FOXG1.
DISCUSSION
Loss of responsiveness to the growth inhibitory effect of TGF-b is a
substantial mechanism in cancer development (Moses et al, 1987).
Apart from genetic and/or epigenetic lesions in TGF-b receptors or
TGF-b/Smad transducers that can contribute to TGF-b resistance
in human cancers (Arai et al, 1998; Ko et al, 1998; Matsushita et al,
1999; Venkatasubbarao et al, 2000; Maurice et al, 2001; Fukushima
et al, 2003; Sakaguchi et al, 2005; Zhong et al, 2006), emerging data
have also suggested that the expressions of viral proto-oncogenes
and oncogenes are capable of inducing TGF-b resistance through
blocking the functions of Smads (Datta and Bagchi, 1994; Hahm
et al, 1999; Mori et al, 2001; Lee et al, 2002; Dowdy et al, 2003;
He et al, 2003; Wang et al, 2008). In this study, we found that
FOXG1 was overexpressed in ovarian cancer cell lines and tissue
samples. Using ovarian cancer cell models, we showed that over-
expressed FOXG1 could suppress the TGF-b/Smad pathway-
induced p21WAF1/CIP1 expression and enhanced cell proliferation
in ovarian cancer cells. These data suggest that FOXG1 is
another oncogene participating in TGF-b resistance through
suppressing p21WAF1/CIP1 expression mediated by TGF/Smad
signalling in ovarian cancer cells.
FOXG1 is highly expressed in the telencephalon and has a
crucial role in both proliferation and differentiation of neocortical
progenitors during brain development (Hanashima et al, 2002;
Muzio and Mallamaci, 2005). Indeed, v-Qin and c-Qin, the
orthologs of FOXG1, have been reported to induce oncogenic
transformation of chicken embryo fibroblasts, suggesting FOXG1
may function as an oncogene in human cancer (Chang et al, 1996;
Li et al, 1997). This is further evidenced by the current reports that
overexpression of FOXG1 is associated with the development of
human medulloblastoma and glioblastoma through abolishing
TGF-b-mediated growth inhibition by suppressing the transcrip-
tion activation of p21WAF1/CIP1 (Seoane et al, 2004; Adesina et al,
2007b). However, these reports just indicate the important roles of
FOXG1 in the development of brain cells and neural tumouri-
genesis. The roles and the oncogenic potential of FOXG1 are rarely
SKOV3
SKOV3
SK-shV
– + – +
– + – +
SK-shC8
SK-shV
10 20
15
10
5
8
6
4
2
0
1 2 3 4 5
Days
1 2 3 4 5
Days
*P<0.05 *P<0.05
*
*
*
*
SK-shC8
Acp-shV
Acp-shC6
Ce
ll g
ro
wt
h 
ra
te
 
(fo
ld 
ch
an
ge
)
Ce
ll g
ro
wt
h 
ra
te
 
(fo
ld 
ch
an
ge
)
Acp-shV Acp-shC6
A2780cp
A2780cp
Acp-shV Acp-shC6
FOXG1
-actin
FOXG1
-actin
SK-shV SK-shC8
p21WAF1/CIP1
p21WAF1/CIP1
GAPDH
TGF-
(100M)
TGF-
(100M)
p21WAF1/CIP1
p21WAF1/CIP1
GAPDH
-actin-actin
A
C
D
B
Figure 6 Depletion of FOXG1 sensitises TGF-b mediated of p21WAF1/CIP1 induction and cell growth inhibition. (A, B) Western blot analysis showed
the reduction of endogenous FOXG1 by FOXG1 shRNAi plasmid, pTER-shFOXG1, SKOV3 and A2780cp ovarian cancer cell lines, respectively. SK-shV
and Acp-shV are their corresponding vector controls. (C) The vector controls and FOXG1 stable knockdown clones of SKOV3 (SK-shV and SK-shC8)
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reported in other human epithelial-derived cancers. In this study,
we showed that FOXG1 exercises an oncogenic function in
attenuating the anti-proliferative control of TGF-b through
negative regulation of p21WAF1/CIP1 expression in ovarian cancer
cells. This suggests that the oncogenic role of FOXG1 contributing
to TGF-b resistance is not only restricted in human medullo-
blastoma and glioblastoma but also extends to other human
epithelial-derived cancers.
TGF-b exerts cell growth inhibitory effects through induction of
the CDK inhibitors p15Ink4b and p21WAF1/CIP1 expressions through
Smad-mediated transcriptional activities (Voss et al, 1999; Feng
et al, 2000). These inhibitors are able to block cyclin and CDKs
from phosphorylating the retinoblastoma protein (Rb), as well as
preventing the progression of the cell cycle (Reynisdottir et al,
1995; Massague et al, 2000). FOXG1 has been shown to inhibit
Smad-mediated induction of p21WAF1/CIP1 expression through
association with FoxO–Smad complexes in the nucleus (Rodriguez
et al, 2001; Seoane et al, 2004; Adesina et al, 2007b). To investigate
the cell growth inhibitory mechanism of FOXG1 on ovarian cancer
cells, we evaluated the p21WAF1/CIP1 expression by quantitative
RT–PCR, western blot and immunohistochemical analyses.
Although we observed that there was an inverse relationship
between the expressions of FOXG1 and p21WAF1/CIP1, no significant
statistical correlation was found. However, this is not surprising
because p21WAF1/CIP1 is usually downregulated in human cancers
and is regulated by p53-dependent and -independent path-
ways (O’Reilly, 2005). Therefore, to exclude the effect of p53 on
p21WAF1/CIP1 expression, we used p21WAF1/CIP1 promoter (trun-
cated without p53-binding site) luciferase reporter assay to study
the effect of FOXG1 on p21WAF1/CIP1 in HEK293T and A2780cp cell
models. Consistent with the findings from FOXG1 on human
medulloblastoma and glioblastoma (Rodriguez et al, 2001; Seoane
et al, 2004; Adesina et al, 2007b), FOXG1 could reduce TGF-b-
mediated p21WAF1/CIP1 expression in a dose-dependent manner.
We also showed that the overexpression or RNAi-mediated
depletion of FOXG1 could alter the expression of p21WAF1/CIP1 in
ovarian cancer cells. This suggests that FOXG1 is able to inhibit
TGF-b-mediated p21WAF1/CIP1 induction and supports its growth
promoting function in ovarian cancer cells.
Recent studies have shown that the phosphorylation of Ser 19
at the N-terminus of FOXG1 promotes nuclear imports of
FOXG1 (Regad et al, 2007). The nuclear FOXG1, in turn, blocks
TGF-b-mediated p21WAF1/CIP1 induction (Seoane et al, 2004). To
investigate whether the inhibitory effect on p21WAF1/CIP1 induction
is due to this mechanism, we evaluated subcellular localisation and
serine phosphorylation status of FOXG1. Our data showed that
higher levels of serine phosphorylation of FOXG1 were consistent
with the accumulation of nuclear FOXG1 in FOXG1-overexpressed
ovarian cancer cell lines (SKOV3 and A2780cp) and Flag-tagged
FOXG1 enforced-expressing cells. However, no change of
FOXG1 nuclear localisation and serine phosphorylation levels
were observed in ovarian cancer cells under TGF-b treatment
(see Supplementary Figure). This indicates that the increased
serine phosphorylation and nuclear localisation of FOXG1 in
FOXG1-overexpressed ovarian cancer cells attribute the inhibition
of TGF-b-mediated p21WAF1/CIP1 induction.
Finally, apart from inhibition on cell proliferation, TGF-b
also induces differentiation and apoptosis in many normal
epithelial cells (Elliott and Blobe, 2005). Loss of TGF-b respon-
siveness has been found in high grade with poor differentiated
human cancers (Tang et al, 2003; Elliott and Blobe, 2005).
Intriguingly, the overexpression of FOXG1 was also significantly
correlated with a higher grade of ovarian cancer and in agree-
ment with the above findings. These findings suggest that
overexpressed FOXG1 suppresses TGF-b responsiveness in ovarian
cancer.
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